What's happening
This bill classifies xylazine as a Schedule III depressant under New York public health law.
Why it matters
Responds to rising public health concerns. Xylazine, originally a veterinary sedative, has been increasingly found mixed with illicit opioids like fentanyl, contributing to a surge in overdose deaths and severe health complications in New York and across the country.
Enables stronger regulation and law enforcement. By classifying xylazine as a Schedule III controlled substance, authorities gain clearer legal grounds to control its distribution, track its use, and prosecute illegal possession or trafficking—steps that have been difficult without explicit scheduling.
Impacts medical and veterinary practices. The new classification will require veterinarians and other medical professionals to adhere to stricter record-keeping, storage, and prescribing standards, possibly affecting how xylazine is accessed and used for legitimate animal care.
Signals legislative attention to emerging drug threats. This amendment demonstrates New York's proactive stance in updating drug laws to address evolving patterns in substance abuse and to close gaps that may be exploited by illicit drug manufacturers and dealers.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Restrict Xylazine as Depressant
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
- Print number 5914a
- Amend and recommit to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Restrict Xylazine Use
In Senate Committee · Health · Sponsor James Skoufis
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
5914--A
2023-2024 Regular Sessions
IN ASSEMBLY
March 24, 2023
Introduced by M. of A. WOERNER -- read once and referred to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to designating Xylazine as a schedule III depressant
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivision (c) of schedule III of section 3306 of the public health law is amended by adding a new paragraph 15 to read as follows:
(15) Xylazine (N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3 thiazin-2- amine), including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.
§ 2. This act shall take effect on the ninetieth day after it shall have become a law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06914-02-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.